Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.37. This compares to loss of $1.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.19%. A quarter ago, it was expected that this company would post a loss of $1.21 per share when it actually produced a loss of $1.31, delivering a surprise of -8.26%.Over the last four quarters, the company h ...

Exhibit 99.1 . L L L PRESS RELEASE Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on track to initiate study by year-end - Strong patient enrollment continues in the MAGNITUDE Phase 3 study of nex-z for ATTR amyloidosis with cardiomyopathy, tracking ahead ...

Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on track to initiate study by year-endStrong patient enrollment continues in the MAGNITUDE Phase 3 study of nex-z for ATTR amyloidosis with cardiomyopathy, tracking ahead of plans Plan to present new clinical data from the ongoing nex-z Phase 1 study at upcoming 2024 American Heart Association Scientific SessionsActiv ...

There's nothing bearish at all about what it reported recently.Sometimes with biotech stocks, what a company considered to be good news clashes with what the market is expecting. That was true on Oct. 24 when Intellia Therapeutics (NTLA 2.56%) announced some positive new clinical trial data only to see its stock slide by 18% -- and the price hasn't fully recovered as of yet.What's causing this disconnect, and could Intellia Therapeutics be a buy now? We'll start by answering the first question.A competitor' ...

Third quarter 2024 financial results – November 7, at 8 a.m. ETNew clinical data from the Phase 1 study of nexiguran ziclumeran (nex-z) for the treatment of transthyretin (ATTR) amyloidosis – November 16, at 11 a.m. CT / 12 p.m. ET CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced it will be hosting two virtual investor events in November ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Call to Discuss NTLA-2002 Phase 2 Study Results Call October 24, 2024 11:00 AM ET Company Participants Lina Li - Senior Director, Investor Relations and Corporate Communications John Leonard - Chief Executive Officer David Lebwohl - Chief Medical Officer. Danny Cohn - Internist, Department of Vascular Medicine, Amsterdam University Medical Center Paula Busse - Professor of Medicine, Division of Clinical Immunology Jim Butler - General Manager, NTLA-2002 Program, Con ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Call to Discuss NTLA-2002 Phase 2 Study Results Call October 24, 2024 11:00 AM ET Company Participants Lina Li - Senior Director, Investor Relations and Corporate Communications John Leonard - Chief Executive Officer David Lebwohl - Chief Medical Officer. Danny Cohn - Internist, Department of Vascular Medicine, Amsterdam University Medical Center Paula Busse - Professor of Medicine, Division of Clinical Immunology Jim Butler - General Manager, NTLA-2002 Program, Con ...

The ever-volatile biotech sector is making noise today. Viking Therapeutics Inc (NASDAQ:VKTX) is soaring up the charts, while Intellia Therapeutics Inc (NASDAQ:NTLA) stumbles.Viking Could Burn Shorts' ShipVKTX is up 24% to trade at $74.75 today, after the company's third-quarter loss came in below analyst estimates. The big driver though is the encouraging pipeline update on its obesity drug, which showed promising results in clinical studies. This is even more notable considering Viking doesn't have an app ...

Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility. Early-stage innovation stocks can be hard on the nerves. Short-sellers frequently pile into these stocks ahead of major catalysts, driving the stock price down significantly. Worst of all, these trough periods can persist for years as companies develop key product candidates, pass through major regulatory hurdles, and prepare to enter the market. However, these stocks c ...

- Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced a new date for its upcoming investor webcast to review the data from the Phase 2 study of NTLA-2002. The webcast will now be held on Thursday, October 24 at 8:30 a.m. ET. The Com ...